Article Text

other Versions

Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort
  1. Manabu Fujimoto1,
  2. Takashi Matsushita1,
  3. Yasuhito Hamaguchi1,
  4. Kenzo Kaji1,
  5. Yoshihide Asano2,
  6. Fumihide Ogawa3,
  7. Toshifumi Yamaoka3,4,
  8. Keita Fujikawa5,
  9. Toshiaki Tsukada5,
  10. Keita Sato6,
  11. Takeshi Echigo7,
  12. Minoru Hasegawa1,
  13. Kazuhiko Takehara1
  1. 1Department of Dermatology, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan
  2. 2Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan
  3. 3Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  4. 4Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan
  5. 5Department of Rheumatology, Isahaya Health Insurance General Hospital, Isahaya, Japan
  6. 6Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo, Japan
  7. 7Division of Dermatology, Noto General Hospital, Nanao, Japan
  1. Correspondence to Dr Manabu Fujimoto, Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan; fujimoto-m{at}

Statistics from

Dermatomyositis (DM) is a heterogeneous disease with varying degrees and time courses of skin eruptions, myositis and internal organ involvement.1 Increasing evidence has demonstrated that myositis-specific autoantibodies (MSAs) are closely associated with distinct clinical subsets.2 Recently, Betteridge et al3 ,4 reported a novel MSA against small ubiquitin-like modifier activating enzyme (SAE) in DM patients. In this study, we detected this autoantibody in a Japanese DM cohort and assessed its clinical correlations.

We screened 456 consecutive Japanese patients with DM (11 children, 445 adults); 373 fulfilled the criteria of Bohan and Peter5 ,6 and the remaining 83 fulfilled Sontheimer's criteria for clinically amyopathic DM (CADM).7 Controls included 62 patients with polymyositis, 108 with systemic lupus erythematosus, 433 with systemic sclerosis and 124 with interstitial lung disease (ILD) alone. The institutional review board approved the study protocol.

Immunoprecipitation …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.